RELATING TO INSURANCE -- PRESCRIPTION DRUG BENEFITS
Impact
The bill is expected to significantly affect how health insurance companies calculate enrollee contributions, potentially lowering these contributions for individuals who face considerable out-of-pocket costs associated with medications. By including third-party payments in the calculations, the bill aims to provide a more accurate and equitable assessment of the financial burden placed on individuals under their health insurance plans, thereby offering a degree of relief to enrollees facing high medication costs.
Summary
House Bill H7947 amends existing legislation related to insurance and prescription drug benefits, specifically addressing the calculation of an enrollee's overall contribution to out-of-pocket maximums and cost-sharing requirements. The bill mandates that insurers and pharmacy benefit managers include any amounts paid by the enrollee or on their behalf by a third party when determining these contributions. The provisions of this bill are set to take effect for health plans entered into, amended, extended, or renewed on or after January 1, 2027.
Contention
While the bill receives support for its intent to alleviate out-of-pocket costs, there may be contention regarding its implementation and effects on health plan pricing. Critics may raise concerns about the fiscal implications for insurers and whether these changes could lead to increased premiums as companies adjust their policies to accommodate the new requirements. Additionally, some stakeholders in the healthcare industry may argue about potential complexities in tracking and reporting the necessary information to comply with the new regulations.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).